13F Holdings
中文EN

TECX Tectonic Therapeutic, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1681087 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-72.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-35.5%
ROA-33.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.0%
Debt / equity0.00x
Current ratio19.71x
Interest coverage-3,216.43x

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$63.49M$41.36M$36.97M$72.19M$83.11M
SG&A expense$20.55M$16.65M$7.68M$33.25M$35.73M
Operating income-$84.04M-$58.02M-$44.65M-$105.43M-$118.84M
Interest expense$63,000$107,000$152,000$1.81M$203,000
Pretax income-$72.92M-$57.98M———
Income tax$1.23M$0$0$0—
Net income-$74.15M-$57.98M-$42.82M-$105.89M-$119.13M
EBITDA-$82.66M-$56.37M-$43.17M-$103.99M-$117.44M
EPS (basic)-4.05-6.83-33.76-2.42-2.78
EPS (diluted)-4.05-6.83-33.76-2.42-2.78
Dividends declared per share0.000.00———
Weighted avg. shares (diluted)18.32M8.49M1.27M43.74M42,854
Balance sheet
Cash & equivalents$253.80M$141.83M$29.36M$36.55M$190.06M
Current assets$257.36M$146.86M$30.88M$99.96M$199.15M
PP&E, net$1.19M$2.15M$3.12M$2.89M$4.13M
Total assets$261.04M$152.91M$39.40M$103.95M$203.84M
Current liabilities$9.67M$11.61M$40.89M$13.12M$19.39M
Long-term debt———$15.00M$15.00M
Total debt———$15.00M$15.00M
Total liabilities$9.71M$12.13M$43.41M$28.58M$34.36M
Shareholders' equity$251.33M$140.78M-$84.64M-$45.65M$169.48M
Net debt———-$21.55M-$175.06M
Shares outstanding18.74M14.86M1.41M43.92M43.65M
Cash flow statement
Operating cash flow-$60.08M-$59.08M-$40.68M-$97.21M-$98.03M
Capital expenditure$208,000$156,000$279,000$267,000$2.46M
Free cash flow-$60.29M-$59.24M-$40.96M-$97.47M-$100.49M
Investing cash flow-$138,000-$156,000-$279,000-$267,000-$2.46M
Financing cash flow$173.35M$171.71M$33.75M$262,000$30.37M
Depreciation & amortization$1.38M$1.65M$1.48M$1.44M$1.40M
Stock-based compensation$10.50M$3.49M$1.12M$11.52M$18.58M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.